Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-92480 |
Synonyms | |
Therapy Description |
CC-92480 binds to and modulates activity of the ubiquitin E3 ligase complex member Cereblon (CRBN), which may induce ubiquitination and degradation of transcription factors in T-lymphocytes, resulting in immune system activation (Blood (2019) 134 (Supplement_1): 1812, PMID: 32130004). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-92480 | CELMoD CC92480|CC 92480|Mezigdomide|BMS-986348|BMS986348|BMS 986348 | CC-92480 binds to and modulates activity of the ubiquitin E3 ligase complex member Cereblon (CRBN), which may induce ubiquitination and degradation of transcription factors in T-lymphocytes, resulting in immune system activation (Blood (2019) 134 (Supplement_1): 1812, PMID: 32130004). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06048250 | Phase I | CC-92480 | Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma | Recruiting | USA | 0 |